TRVI

Trevi Therapeutics, Inc.

TRVI | $2.705 0.75% 35K

(0.0% 1d) (-24.0% 1m) (-1.1% 1y) (0.0% 2d) (4.3% 3d) (-4.3% 7d) (-28.37% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 186,537,252
http://www.trevitherapeutics.com
Sec Filling | Patents | 17 employees

Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.

chronic cough fibrosis parkinson neurological treatment

add to watch list Paper trade email alert is off

Press-releases

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
TRVI | $2.705 0.75% 35K

Health Technology

| -12.23% | O: 2.77% H: 1.59% C: -8.57%
conference presentation international therapeutics

Trevi Therapeutics to Participate in Upcoming April Events
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
TRVI | $2.705 0.75% 35K

Health Technology

| -14.87% | O: 0.0% H: 2.85% C: -1.74%
therapeutics

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Published: 2024-03-20 (Crawled : 20:00) - prnewswire.com
TRVI | $2.705 0.75% 35K

Health Technology

| -24.01% | O: -1.98% H: 15.27% C: 6.63%
business year therapeutics financial results

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
Published: 2024-03-13 (Crawled : 20:00) - prnewswire.com
TRVI | $2.705 0.75% 35K

Health Technology

| -9.43% | O: -1.35% H: 8.87% C: 6.83%
report year update therapeutics financial results

Trevi Therapeutics to Participate in Upcoming March Events
Published: 2024-02-28 (Crawled : 12:30) - prnewswire.com
TRVI | $2.705 0.75% 35K

Health Technology

| -2.89% | O: 1.81% H: 6.74% C: 3.9%
therapeutics

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-06 (Crawled : 12:30) - prnewswire.com
TRVI | $2.705 0.75% 35K

Health Technology

| 92.14% | O: 0.0% H: 5.0% C: 4.29%
conference life sciences therapeutics

Trevi Therapeutics Provides Business Updates
Published: 2024-01-04 (Crawled : 12:30) - prnewswire.com
TRVI | $2.705 0.75% 35K

Health Technology

| 105.34% | O: 2.29% H: 5.22% C: 2.99%
business therapeutics

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
Published: 2023-12-05 (Crawled : 12:30) - prnewswire.com
TRVI | $2.705 0.75% 35K

Health Technology

| 142.34% | O: 2.7% H: 0.0% C: -6.14%
fibrosis trial therapeutics

Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-09 (Crawled : 21:00) - prnewswire.com
TRVI | $2.705 0.75% 35K

Health Technology

| 98.52% | O: 4.06% H: 2.83% C: -7.09%
business update therapeutics financial results

Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
Published: 2023-11-01 (Crawled : 20:00) - prnewswire.com
TRVI | $2.705 0.75% 35K

Health Technology

| 52.84% | O: 3.41% H: 1.1% C: -8.79%
report update therapeutics financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-23-042078	4	2023-07-12	2023-07-11	Sell	M	2292	71043
0001209191-23-042078	4	2023-07-12	2023-07-11	Sell	S	687	31204
0001209191-23-042078	4	2023-07-12	2023-07-11	Buy	M	2292	31891